32 Recruiting Studies Using Exemestane
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Exemestane
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
View Study & Checklist ➔Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
📍 Marin Cancer Care, Inc — Greenbrae, California
Breast Cancer
View Study & Checklist ➔OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
📍 Clinical Trial Site — Tucson, Arizona
Breast Cancer
View Study & Checklist ➔An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
📍 Research Site — Dothan, Alabama
Breast Cancer, Early Breast Cancer
View Study & Checklist ➔Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
📍 Cedars-Sinai Medical Center — Los Angeles, California
Adult Ovarian Granulosa Cell Tumor
View Study & Checklist ➔Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist ➔S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
📍 Northeast Alabama Regional Medical Center — Anniston, Alabama
Breast Ductal Carcinoma In Situ
View Study & Checklist ➔A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
📍 Highlands Oncology Group - Duplicate 2 — Rogers, Arkansas
Breast Neoplasms
View Study & Checklist ➔Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
📍 UCSF — San Francisco, California
HER-2 Positive Breast Cancer
View Study & Checklist ➔Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
📍 Northeast Alabama Regional Medical Center — Anniston, Alabama
Breast Adenocarcinoma
View Study & Checklist ➔Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
📍 City of Hope - Phoenix ( Site 0006) — Goodyear, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
📍 Stamford Hospital — Stamford, Connecticut
Breast Cancer
View Study & Checklist ➔A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
📍 Hoag Health Center Irvine — Irvine, California
Advanced or Metastatic Breast Cancer
View Study & Checklist ➔A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
Breast Neoplasms
View Study & Checklist ➔A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
📍 USO - Southern Cancer Center — Daphne, Alabama
Breast Neoplasms
View Study & Checklist ➔Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
📍 Brigham and Women's Hospital — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
📍 Siteman Cancer Center at Washington University — St Louis, Missouri
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist ➔Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
📍 Central Alabama Research — Birmingham, Alabama
Early Breast Cancer
View Study & Checklist ➔A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
📍 Southern Cancer Center, PC — Daphne, Alabama
Breast Cancer
View Study & Checklist ➔Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
📍 NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
📍 Ellison Clinic at Saint John's — Los Angeles, California
Breast Cancer
View Study & Checklist ➔DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
📍 Berkeley Outpatient Center — Berkeley, California
Ductal Carcinoma in Situ
View Study & Checklist ➔Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
📍 Yale School of Medicine — New Haven, Connecticut
Hormone Receptor-positive Breast Cancer
View Study & Checklist ➔Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
📍 Washington University School of Medicine — St Louis, Missouri
Breast Cancer
View Study & Checklist ➔A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
📍 Alaska Oncology and Hematology — Anchorage, Alaska
Breast Neoplasms
View Study & Checklist ➔Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Locoregional Recurrence
View Study & Checklist ➔A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
📍 Research Site — Birmingham, Alabama
Breast Cancer, Early Breast Cancer
View Study & Checklist ➔E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study
📍 UNC Fertility — Raleigh, North Carolina
Poly Cystic Ovary Syndrome
View Study & Checklist ➔A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
Breast Cancer
View Study & Checklist ➔A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
📍 Alaska Womens Cancer Care ( Site 0037) — Anchorage, Alaska
Malignant Neoplasm
View Study & Checklist ➔Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
📍 Research Site — Gilbert, Arizona
Advanced Breast Cancer
View Study & Checklist ➔